Search

Given the interest around the use of stem cells in ALS, the ENCALS neurologists from across Europe have reviewed the published evidence around the Brainstorm Therapeutics treatment, NurOwn (debamestrocel), and discussed this at a meeting on 13 July 2023.

The consensus view of TRICALS neurologists is that Tofersen shows clear benefit for people with ALS due to SOD1 mutation, especially if given early in the disease course, and support should be given for licensing in this group of patients.

3FM Serious Request is taking action for the ALS Foundation Netherlands during the week of December 17 to December 24. True to tradition, 3FM is taking action for charity in the week before Christmas and the DJs, together with the whole of the Netherlands, are working day and night to raise as much money as possible...

The UK government has recently announced that £50 million will be invested in research to help find a cure for ALS. The funding forms part of a wider £375 million investment for innovative research for neurodegenerative diseases. It will be made available over the next five years to (TRICALS) researchers in the UK a...

Dr Ruben van Eijk (UMC Utrecht) has been awarded the prestigious Paulo Gontijo Award. He received the prize during the virtual 31st International Symposium on ALS/MND. The award means international recognition for his ground-breaking research into the eligibility criteria for ALS clinical trials.

Many clinical trials are looking for participants. In this new interview series, we tell the stories of people who are participating in one of our studies. Why did they choose to participate? And how do they experience their participation? This time we spoke with Peter Ambühl. Peter is participating in a clinical tr...

TRICALS has received the exciting news that the European Medicines Agency (EMA) endorses our plans for an innovative platform trial. Clinical trials investigating candidate medicines for ALS are costly, lengthy and often inaccessible for the majority of patients. This complicates and delays our search for effective ...

Over 70 compounds have been evaluated by clinical studies, yet Riluzole is the only available treatment for people with ALS in Europe. The reasons for this unsuccessful road of drug development are many, including flawed clinical trial design, poor bench-to-bedside translation and the need for more robust biomarkers...